J F QUEVEDO M.D. NPI 1154300226

NPI Information

  • NPI: 1154300226
  • Provider Name: J F QUEVEDO, M.D.
  • Classification: Internal Medicine - 207RX0202X
  • Specialization: Medical Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 200 1ST ST SW
    ROCHESTER, MN
    ZIP 55905
  • Phone: (507) 284-2511

Map and Directions

Get Directions

NPI Details

J F Quevedo, M.D. is a medical oncology internal medicine in Rochester, MN with 41 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. J F Quevedo, M.D. NPI is 1154300226. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

200 1ST ST SW
ROCHESTER, MN
ZIP 55905-001
Phone: (507) 284-2511

The NPI 1154300226 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, fosaprepitant, 1 mg (HCPCS:J1453)
  • Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
  • Injection, paclitaxel, 1 mg (HCPCS:J9267)
  • Injection, bendamustine hcl (bendeka), 1 mg (HCPCS:J9034)
  • Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
  • Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
  • Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
  • Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Injection, fluorouracil, 500 mg (HCPCS:J9190)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
  • Injection, carboplatin, 50 mg (HCPCS:J9045)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Unclassified drugs (HCPCS:J3490)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
  • Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
  • Application of on-body injector for under skin injection (HCPCS:96377)
  • Administration of chemotherapy into vein using push technique (HCPCS:96409)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)

The enumeration date for this NPI number is 1/17/2006 and was last updated on 8/19/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RH0003XInternal MedicineHematology & Oncology33902MINNESOTANo
2207RX0202XInternal MedicineMedical Oncology33902MINNESOTAYes

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.